Activity & safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) origin, & gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who have progressed on prior treatment (Tx)

Beitrag bei einer Tagung


Details zur Publikation

Autorinnen und Autoren: Yao JC, Strosberg J, Fazio N, Pavel ME, Ruszniewski P, Bergsland E, Li D, Tafuto S, Raj N, Campana D, Hijioka S, Raderer M, Guimbaud R, Gajate P, Pusceddu S, Reising A, Degtyarev E, Mookerjee B, Aimone P, Singh S
Verlag: OXFORD UNIV PRESS
Verlagsort: OXFORD
Jahr der Veröffentlichung: 2018
Tagungsband: ANNALS OF ONCOLOGY
ISSN: 0923-7534


FAU-Autorinnen und Autoren / FAU-Herausgeberinnen und Herausgeber

Pavel, Marianne Ellen
Professur für Endokrinologie


Einrichtungen weiterer Autorinnen und Autoren

Aichi Cancer Center Research Institute
Beaujon Hospital / Hôpital Beaujon
Centre Hospitalier Universitaire (CHU) de Toulouse
City of Hope Medical Center
European Institute of Oncology / Istituto Europeo di Oncologia (IEO)
Fondazione IRCCS: Istituto Nazionale dei Tumori
H. Lee Moffitt Cancer Center & Research Institute
Hospital Universitario Ramón y Cajal
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
Medizinische Universität Wien
Memorial Sloan Kettering Cancer Center
Novartis AG
Policlinico Sant'Orsola-Malpighi
Sunnybrook Health Sciences Centre
UCSF Helen Diller Family Comprehensive Cancer Center
University of Texas MD Anderson Cancer Center


Zitierweisen

APA:
Yao, J.C., Strosberg, J., Fazio, N., Pavel, M.E., Ruszniewski, P., Bergsland, E.,... Singh, S. (2018). Activity & safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) origin, & gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who have progressed on prior treatment (Tx). In ANNALS OF ONCOLOGY. Munich, DE: OXFORD: OXFORD UNIV PRESS.

MLA:
Yao, J. C., et al. "Activity & safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) origin, & gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who have progressed on prior treatment (Tx)." Proceedings of the 43rd ESMO Congress (ESMO), Munich OXFORD: OXFORD UNIV PRESS, 2018.

BibTeX: 

Zuletzt aktualisiert 2019-12-03 um 09:23